Outcomes after lung transplantation and practices of lung transplant programs in the united states regarding hepatitis C seropositive recipients

Transplantation

Volumn 91, Issue 11, 2011, Pages 1293-1296

  Fong, Tse Ling ^a,c   Cho, Yong W ^a,b   Hou, Linda ^a   Hutchinson, Ian V ^b   Barbers, Richard G ^c   Herrington, Cynthia S ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b National Institute of Transplantation Los Angeles   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chronic hepatitis C; Graft survival; Lung transplant

Indexed keywords

CREATININE;

ADULT; AGE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA BASE; FEMALE; GRAFT SURVIVAL; HEALTH STATUS; HEALTH SURVEY; HEPATITIS C; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; ORGAN DONOR; PRIORITY JOURNAL; SENSITIZATION; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LUNG TRANSPLANTATION; MIDDLE AGED; PREVALENCE; RNA, VIRAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 79958276680     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182193cd3     Document Type: Article

References (21)

1. http://www.unos.org/data. Accessed February 1, 2010.
2. http://www.ustransplant.org/annual-reports/current/112b-dh.pdf. Accessed February 8, 2010.
3. Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6: 1212.
4. Ghany MG, Stader DB, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C. An update. Hepatology 2009; 49: 1335.
5. Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: A survey of practices. J Heart Lung Transplant 1999; 18: 456.
6. Carreno MC, Piedad UG, Maite L, et al. HepatitisCvirus infection after lung transplantation: Dim prognosis. J Heart Lung Transplant 2001; 20: 224.
7. Fabrizi F, Martin P, Dixet V, et al. Hepatitis C antibody status and survival after renal transplantation: Meta analysis of observational studies. Am J Transplant 2005; 5: 1452.
8. Terrault NA, Adey DB. The kidney transplant recipient with hepatitisC infection: Pre- and posttransplant treatment. Clin J Am Soc Nephrol 2007; 2: 563.
9. Fong TL, Hou L, Hutchinson IV, et al. Impact of hepatitis C on outcomes after heart transplantation. Transplantation 2009; 88: 1137.
10. American Society for Transplant Physicians; American Thoracic Society; European Respiratory Society; International Society for Heart and Lung Transplantation. International Guidelines for the Selection of Lung Transplant Candidates.AmJ Respir Crit Care Med 1998; 158: 335.
11. Orens JB, Estenne M, Arcasoy S, et al.; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-A consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745.
12. Sahi H, Zein NN, Mehta AC, et al. Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J Heart Lung Transplant 2007; 26: 466.
13. Doucette KE, Weinkauf J, Sumner S, et al. Treatment of hepatitis C in potential lung transplant candidates. Transplantation 2007; 83: 1652.
14. Ceballos-Viro J, Ló pez-Picazo JM, Pérez-Gracia JL, et al. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J Gastroenterol 2009; 15: 2290.
15. Fong T-L, Valinluck B, Govindarajan S, et al. Effects of prednisone therapy on aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196.
16. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209.
17. Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83: 1224.
18. Delgado J, de Busstillo EM, Ibarrola C, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardaic transplantation. J Heart Lung Transplant 1999; 18: 607.
19. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitisC virus infection in heart transplant recipients. Hepatology 1999; 30: 1293.
20. Giannini EG, Basso M, Savarino V, et al. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502.
21. Fong TL, Lee SR, Briggs WK, et al. Clinical significance of hepatitis C viral RNA status and its correlation to antibodies to structural HCV antigens in anti-HCV reactive patients with normal liver tests. J Med Virol 1996; 49: 253.